Navigation Links
Termination of IS Clinical From Distributing PhytoCeuticals Formulas
Date:7/2/2008

ELMWOOD PARK, N.J., July 2 /PRNewswire/ -- PhytoCeuticals, Inc., the highly respected developer and manufacturer of proprietary skin care formulations, who is the Fast to invent Stable Liquid L-Ascorbic Acid (Vitamin C), has terminated the agreement granting IS Clinical from Innovative Skin Care the right to exclusively market the proprietary product formulas of PhytoCeuticals, Inc. effective July 1, 2008.

The IS Clinical termination was triggered by that company's introduction of controversial new products, not created by PhytoCeuticals, Inc. that violated Dr. Mostafa M. Omar, presidents of PhytoCeuticals, Inc. medical guidelines. Dr. Omar is also the Professor of Pharmacognosy at the University of Rhode Island, School of Pharmacy commented, "It is my ethical duty as a prominent medical researcher to warn clinicians and patients that, as IS Clinical no longer has access to PhytoCeuticals, Inc. formulas and products, I cannot warrant the safety of any products sold by IS Clinical."

IS Clinical has received legal notice to remove all references to Dr. Omar and/or PhytoCeuticals, Inc., including all research citations, product claims and other related materials from all websites, advertising materials, media releases, packaging and product literature. Also IS Clinical is required to issue a clarifying press release informing clinicians and consumers, which products sold by the company prior to July 1, 2008, were actually owned and developed by PhytoCeuticals, Inc. -- a business relationship that no longer exists.

"We will take all action necessary to prohibit IS Clinical from illegal usage of our formulas and research,' added Dr. Omar. "We will protect our scientific integrity and the reputation of our unique, clinically-proven products by any and all legal means."

PhytoCeuticals, Inc. is highly respected developer and manufacturing of proprietary skin care formulations, who is the First to invent Stable Liquid L-Ascorbic Acid (Vitamin C) in the market place in early 1990. The company had awarded many grants from National Cancer Institute (NCI) and National Institute of Health (NIH) to test all its formulations clinically over 18 years. The products are no longer available from IS Clinical but directly from PhytoCeuticals, Inc.

1. Active Serum

2. Hydra cool gel

3. Polyvitamin gel

4. Skin Firming Cream

5. Eye Contour Cream

6. Body Lotion

7. Topical Vitamin C Eye Gel

8. Topical Vitamin C 15% Serum

9. Topical Vitamin C&E Serum

10. Proheal Serum (Topical Vitamin C,E,A, Olive Leaves Extract).

11. Super Serum.

12. Moisturizing Cream

For further information, please contact Dr. Mostafa M. Omar, the President of PhytoCeuticals, Inc. directly at 201-791-2255 or phytoceuticals@msn.com.


'/>"/>
SOURCE PhytoCeuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Schering-Plough and Merck Announce Withdrawal of Loratadine/Montelukast NDA and Termination of Respiratory Joint Venture
2. Hologic, Inc. Announces Grant of Early Termination of Antitrust Waiting Period for Third Wave Technologies, Inc. Tender Offer
3. Sun Pharma Responds to Taros Purported Termination of Merger Agreement
4. Spinal Surgery and Determination Save Lioness
5. Elbit Imaging Ltd. Announces Termination of Service of Trustee for Holders of Series A, B and C Notes
6. Inaugural Stanford International Pro-Am Winner A Remarkable Story in Determination And the Powerful Impact of St. Jude Childrens Research Hospital
7. Methodist Healthcare - Memphis Hospitals Announces Termination of Tender Offers
8. VaxGen Restructures Following Termination of Proposed Merger
9. Reynolds American Subsidiary to Receive Payment Following Gallaher Joint-Venture Termination
10. TeamStaff Receives Nasdaq Determination Letter
11. IDM Pharma Announces Termination of UVIDEM Development Collaboration and Expected Restructuring in Connection With Evaluation of Strategic Alternatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Atlanta, GA (PRWEB) , ... February 21, 2017 ... ... firm, announced the acquisition of the predictive analytic firm Predixion’s Healthcare IT practice. ... of investment and is backed by giants including Accenture, GE Ventures, ...
(Date:2/21/2017)... Trenton, NJ (PRWEB) , ... February 21, 2017 , ... ... to a healthy lifestyle and make small changes that can lead to a lifetime ... for the possibility of a cardiac emergency. , The Athletic Trainers’ Society ...
(Date:2/20/2017)... ALEXANDRIA, VA (PRWEB) , ... February 20, 2017 , ... ... with Cambridge Healthcare to open and operate a state-of-the-art memory care community in Alexandria, ... of 2018 on a site just outside of Old Town. , The three-story ...
(Date:2/20/2017)... ... February 20, 2017 , ... The StayWell Company ... health care providers better manage patient health risks, foster behavior change and improve health ... in the world, will present a demonstration of its video capability at StayWell booth ...
(Date:2/20/2017)... ... February 20, 2017 , ... Houston dentist , ... dental care at his office, Antoine Dental Center. Emergency dentistry encompasses many treatments ... are at risk for serious complications and often experience severe pain. Not only ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... MELBOURNE, Australia , Feb. 21, 2017  IBM (NYSE: ... IBM Watson,s ability to detect abnormalities of the eye,s retina. ... trained a research version of Watson to recognize abnormalities in ... insights and speed in their early identification of patients who ... glaucoma, a leading cause of blindness in the developed world. ...
(Date:2/21/2017)... Medical Oxygen Concentrators Market: Overview ... Medical oxygen concentrators are used by patients ... having low level of oxygen in their blood ... are to be used only with prescription and ... concentrators work either on rechargeable lithium batteries or ...
(Date:2/21/2017)...   BeyondSpring Pharmaceuticals , a clinical stage ... immuno-oncology cancer therapies, today announced that the Company,s ... 2 trial of BeyondSpring,s innovative lead asset, ... lung cancer (NSCLC) with Docetaxel has been selected ... Immuno-Oncology Symposium in Orlando, Fla. ...
Breaking Medicine Technology: